MEDICORTEX
26.4.2017 09:36:11 CEST | Business Wire | Press release
Every time a professional football player makes headlines because of a severe concussion sustained on the playing field, a researcher and neurobiologist Dr. Adrian Harel is reminded of the urgent need for more effective protocols to diagnose and treat traumatic brain injury (TBI). Dr. Harel and his team are intensely pursuing breakthrough rapid diagnostic test and treatments for TBI with a new class of drugs. “What so many people fail to realize is that even if a player isn’t thrown into a coma or vegetative state by the injury, TBI can have long-lasting effects that may ultimately end in tragedy.” Dr. Harel says.
Sports-related TBI among professional athletes is a serious problem. In the US alone, there are annually more than 300,000 cases where athletes are suffering from concussion and TBIs that result in loss of consciousness.
The medical community is well aware of the importance of early intervention in all forms and degrees of TBI. “We are simply seeing too many of our best athletes [ice-hockey, rugby, football, boxing ] permanently brain-damaged,” says Dr. Harel, “not to mention the millions of other cases of TBI sustained by people of all ages as a result of vehicle crashes, falls, workplace accidents, and assaults or physical abuse. TBI is a major problem in search of a comprehensive solution. With the research we are doing now, there is finally a light at the end of the tunnel.”
Medicortex is seeking investors, together with its crowdfunding campaign. Every interested individual may help the development of the diagnostic kit by participating the crowdfunding campaign at: www.invesdor.com/medicortex Medicortex is issuing shares with the goal of raising capital that matches the other half that the firm has already applied for from the Finnish Funding Agency for Innovation (Tekes).
About Medicortex:
Medicortex Finland Oy (http://www.medicortex.fi ) is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is to develop biomarker diagnostics that evaluate the extent and severity of TBI. Once the company completes this test its next goal will be to develop an innovative drug to halt the progression of brain injury.
Key words: NFL, ice-hockey, rugby, brain injury, head injury, concussion, diagnostics, TBI, sport, professional athletes, boxing, early detection
View source version on businesswire.com: http://www.businesswire.com/news/home/20170426005548/en/
Contact:
Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358
(0) 400488817
adrian.harel@medicortex.fi
www.medicortex.fi
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Partners Issues Public Shareholder Letter and Submits Formal Shareholder Proposals to DB Insurance9.2.2026 15:26:00 CET | Press release
Align Partners underscores DBI’s persistent undervaluation (0.40x Adjusted PBR), despite industry-leading profitability, identifying inefficient capital allocation and governance issues as primary driversAlign Partners outlines measures for capital efficiency and governance normalization; requests a revised “Value-up” plan and a formal response from the Board by March 6, 2026The proposals nominate two Independent Directors via separate election and calls for the reinstatement of the Internal Transaction Committee Align Partners Capital Management Inc. (“Align Partners”), a shareholder of DB Insurance Co., Ltd. (KRX:005830) (“DBI” or the “Company”) holding 1.9%, has issued a public shareholder letter to DBI’s Board of Directors aimed at strengthening capital allocation policy and governance oversight, and submitted formal shareholder proposals for the 2026 Annual General Meeting (“AGM”). Despite DBI’s robust fundamentals—including a 16.1% ROE and a 226% K-ICS ratio—the Company trades at
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 13:00:00 CET | Press release
TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 13:00:00 CET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 11:37:00 CET | Press release
New Hard Pure Gold Pavilion showcases breakthrough gold technologies Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming
FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 11:30:00 CET | Press release
The initiative will see FlexTrade FX clients seamlessly access CME Group’s primary FX markets within FlexFX. FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
